Pain & Inflammation. Antibe currently has three drug candidates addressing a variety of conditions associated with degenerative disease and inflammation. Our lead candidate, ATB-346 (in Phase 2), is a naproxen derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than is typically associated with NSAID use.

Regenerative Medicine. Antibe is pursuing both internal development and licensing opportunities to support growth of its regenerative medicine portfolio targeting tissue regeneration in oral and maxillofacial surgery. Typically these products are regulated as medical devices (ie. 510(k) pathway) and can typically obtain regulatory clearance within 12 months.

all dollar amounts stated in USD
CANDIDATE TARGET INDICATION PARTNER STATUS MARKET NICHE STATUS MARKET SIZE
PAIN & INFLAMMATION: Oral Therapeutics
ATB-346 Acute & chronic pain Antibe Osteoarthritis, rheumatoid arthritis, etc. Phase 2 $11B
ATB-352 Acute pain Antibe Gout, dental pain, post-surgical pain, etc. Pre-clinical $5B
ATB-340 Anti-thrombotic Antibe Stroke prevention, cancer prevention Pre-clinical $6B
REGENERATIVE MEDICINE: Medical Devices
CGX-227 Bone regeneration Antibe Demineralized bone putty for oral and maxillofacial surgery Pre-clinical $350M
CGX-443 Bone regeneration Antibe Amniotic membrane for oral and maxillofacial surgery Pre-clinical $250M
URISTTM (CGX-276) Bone regeneration Partnered(1) Synthetic BMP-releasing putty for oral and maxillofacial surgery Clinical development $1B
1) Antibe licensed the exclusive Canadian distribution rights for URISTTM for oral & maxillofacial surgery from Induce Biologics in Jan/16.